353 related articles for article (PubMed ID: 35384008)
21. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
[TBL] [Abstract][Full Text] [Related]
22. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.
Chewcharat A; Takkavatakarn K; Isaranuwatchai S; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
Int Urol Nephrol; 2020 Sep; 52(9):1733-1745. PubMed ID: 32524495
[TBL] [Abstract][Full Text] [Related]
23. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.
González-González JG; Díaz González-Colmenero A; Millán-Alanís JM; Lytvyn L; Solis RC; Mustafa RA; Palmer SC; Li S; Hao Q; Alvarez-Villalobos NA; Vandvik PO; Rodríguez-Gutiérrez R
BMJ Open; 2021 Jul; 11(7):e049130. PubMed ID: 34244276
[TBL] [Abstract][Full Text] [Related]
24. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
25. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
26. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
Meade LT; Mannka ML
Ann Pharmacother; 2019 Nov; 53(11):1111-1116. PubMed ID: 31215219
[No Abstract] [Full Text] [Related]
28. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
29. Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials.
Ahmad E; Arsenyadis F; Almaqhawi A; Barker M; Jobanputra R; Sargeant JA; Webb DR; Yates T; Davies MJ
Diabet Med; 2023 Jun; 40(6):e15083. PubMed ID: 36905324
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
Ahmad A; Sabbour H
Cardiovasc Diabetol; 2024 Mar; 23(1):99. PubMed ID: 38500154
[TBL] [Abstract][Full Text] [Related]
31. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y
Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884
[TBL] [Abstract][Full Text] [Related]
32. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
de Wit HM; Te Groen M; Rovers MM; Tack CJ
Br J Clin Pharmacol; 2016 Jul; 82(1):301-14. PubMed ID: 26935973
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Ma R; Ding X; Wang Y; Deng Y; Sun A
Medicine (Baltimore); 2021 Jun; 100(23):e26295. PubMed ID: 34115034
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
[TBL] [Abstract][Full Text] [Related]
35. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
Yan H; Huang C; Shen X; Li J; Zhou S; Li W
Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
[TBL] [Abstract][Full Text] [Related]
36. Weight loss differences seen between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for treatment of type 2 diabetes.
Frieling K; Monte SV; Jacobs D; Albanese NP
J Am Pharm Assoc (2003); 2021; 61(6):772-777. PubMed ID: 34266747
[TBL] [Abstract][Full Text] [Related]
37. Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Liakos CI; Papadopoulos DP; Sanidas EA; Markou MI; Hatziagelaki EE; Grassos CA; Velliou ML; Barbetseas JD
Am J Cardiovasc Drugs; 2021 Mar; 21(2):123-137. PubMed ID: 32780214
[TBL] [Abstract][Full Text] [Related]
38. Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.
Premji R; Nylen ES; Naser N; Gandhi S; Burman KD; Sen S
Metab Syndr Relat Disord; 2022 Aug; 20(6):321-328. PubMed ID: 35452324
[TBL] [Abstract][Full Text] [Related]
39. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.
Singh AK; Singh R; Saboo B; Misra A
Diabetes Metab Syndr; 2021; 15(1):159-167. PubMed ID: 33352455
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
Lim S; Kim KM; Nauck MA
Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]